Stocks of the Hour: Dotz Nano, Immuron, Avecho Biotechnology
Stocks of the Hour: Dotz Nano, Immuron, Avecho Biotechnology
To register for Friday's webinar click here.
要註冊參加週五的網絡研討會，請單擊此處。
Dotz Nano (ASX:DTZ, OTC:DTZNY), a leading developer of innovative climate and industrial nanotechnologies, today announced the completion of a bench-scale demonstration unit for its carbon capture technology, Dotz Earth. Validation testing and process simulation results of Dotz's proprietary nano-porous carbon sorbent demonstrated enhanced properties compared with commercial carbon-based sorbents: greater adsorption capacity, better selectivity, and a reduction in regeneration energy. Shares are trading 3.03 per cent higher at 17 cents.
創新氣候和工業納米技術的領先開發商Dotz Nano（澳大利亞證券交易所股票代碼：DTZNY，場外交易代碼：DTZNY）今天宣佈其碳捕集技術Dotz Earth的基準規模演示裝置竣工。Dotz 專有的納米多孔碳吸附劑的驗證測試和過程模擬結果表明，與商用碳基吸附劑相比，其特性更強：更大的吸附能力、更好的選擇性以及更低的再生能量。股價上漲3.03％，至17美分。
Immuron (ASX:IMC; NASDAQ:IMRN) announced that the interim topline results confirming that a single daily dose of Travelan is effective in prevention of moderate to severe diarrhoea following challenge with enterotoxigenic Escherichia coli (ETEC). This interim analysis summarises the data for a total of 60 subjects who have completed the inpatient challenge component of this current clinical study. Shares are trading 51.52 per cent higher at 10 cents.
Immuron（澳大利亞證券交易所股票代碼：IMC；納斯達克股票代碼：IMRN）宣佈，中期頭條結果證實，在受到腸毒素大腸桿菌（ETEC）挑戰後，每日單劑量的Travelan可有效預防中度至重度腹瀉。該中期分析總結了完成當前臨床研究住院挑戰部分的總共60名受試者的數據。股價上漲51.52％，至10美分。
Avecho Biotechnology (ASX:AVE) announced it has received Ethics Approval for its pivotal Phase III clinical trial testing its oral CBD TPM-enhanced soft-gel capsule for insomnia, after the Company submitted amendments to the study in December 2023. The patient recruitment for the Phase III is on track to commence this month for clinical trial sites located in Melbourne, Sydney, Central Coast, Brisbane, and Perth. Shares are trading 33.33 per cent higher at 0.4 cents.
Avecho Biotechnology (ASX: AVE) 宣佈，其關鍵的三期臨床試驗已獲得倫理批准，該試驗的口服CBD TPM增強型軟凝膠膠囊治療失眠症，此前該公司於2023年12月提交了該研究的修正案。位於墨爾本、悉尼、中央海岸、布里斯班和珀斯的臨床試驗地點的三期患者招募工作有望在本月開始。股價上漲33.33％，至0.4美分。
